57 results
Page 3 of 3
8-K
EX-99.1
e6da0563ecd48espbm3
11 May 21
Regulation FD Disclosure
11:42am
8-K
EX-99.1
06qui3qjc
15 Apr 21
Regulation FD Disclosure
9:08am
8-K
EX-99.1
fy8mom6dhh4a
13 Apr 21
Longeveron Announces Positive Results of Phase I Clinical Study of Lomecel-B Cell Therapy for Alzheimer’s Disease
9:18am
10-K
2oqvpyv7o 2i
30 Mar 21
Annual report
4:51pm
8-K
EX-99.1
126pb 9kqf1
30 Mar 21
Longeveron Provides Corporate Update and Reports Fourth Quarter and Full Year 2020 Financial Results
9:03am
8-K
EX-99.1
a9nu36
15 Mar 21
Longeveron Inc. Announces Partial Exercise of Over-Allotment Option in Initial Public Offering
4:30pm
8-K
EX-10.1
17fvm17p
9 Mar 21
Longeveron and University of Miami Expand Exclusive License Agreement, and Enter into CRADA To Facilitate Future Collaborations
4:21pm
8-K
EX-10.2
k94ril95ytyrniiu03u
9 Mar 21
Longeveron and University of Miami Expand Exclusive License Agreement, and Enter into CRADA To Facilitate Future Collaborations
4:21pm
8-K
EX-99.1
mmp4nhq6cr 2nk03a
9 Mar 21
Longeveron and University of Miami Expand Exclusive License Agreement, and Enter into CRADA To Facilitate Future Collaborations
4:21pm
424B4
qi6up2v89d
12 Feb 21
Prospectus supplement with pricing info
4:09pm
FWP
x2hjvyh 9r7g
3 Feb 21
Free writing prospectus
5:01pm
S-1/A
h63udge0oi w7
3 Feb 21
IPO registration (amended)
4:57pm
S-1
xit0wt5r
19 Jan 21
IPO registration
5:21pm
DRS/A
6150687k
30 Dec 20
Draft registration statement (amended)
12:00am
DRS
qshrokfia2tb6 a491
12 Nov 20
Draft registration statement
12:00am